menu
    • menu

    Company profile for Dragonfly Therapeutics

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dragonfly's therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses, and are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies – such as T cell treatments.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dragonfly TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    35 Gatehouse Drive Waltham, MA 02451
    Telephone
    Telephone
    617-588-0086
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dragonflytx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abbvie Halts Development Of Dragonfly Cancer Asset In Midflight
    Abbvie Halts Development Of Dragonfly Cancer Asset In Midflight

    29 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/abbvie-halts-development-licensed-dragonfly-cancer-asset-midflight

    FIERCE BIOTECH
    29 Oct 2025
    Share Share
    Dragonfly Therapeutics Presents DF6215 Preclinical Data at SITC
    Dragonfly Therapeutics Presents DF6215 Preclinical Data at SITC

    07 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dynavax-announces-200-million-share-repurchase-program-302298340.html

    PR NEWSWIRE
    07 Nov 2024
    Share Share
    Dragonfly Presents Preclinical Data on DF6215 & DF9001 at SITC
    Dragonfly Presents Preclinical Data on DF6215 & DF9001 at SITC

    07 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dragonfly-therapeutics-to-present-preclinical-data-on-clinical-stage-df6215-its-engineered-il-2r-alpha-active-agonist-and-df9001-its-egfr-targeting-trinket-at-the-society-for-immunotherapy-of-cancer-sitc-annual-conference-302299009.html

    PR NEWSWIRE
    07 Nov 2024
    Share Share
    Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer
    Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer

    05 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dragonfly-therapeutics-appoints-dr-susan-altschuller-as-chief-financial-officer-302213947.html

    PR NEWSWIRE
    05 Aug 2024
    Share Share
    Dragonfly, Merck Collaborate On DF9001 TriNKET Plus KEYTRUDA
    Dragonfly, Merck Collaborate On DF9001 TriNKET Plus KEYTRUDA

    21 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dragonfly-therapeutics-inc-announces-clinical-collaboration-to-evaluate-df9001-an-egfr-targeting-trinket-in-combination-with-keytruda-pembrolizumab-in-patients-with-solid-tumors-302150767.html

    PR NEWSWIRE
    21 May 2024
    Share Share
    Dragonfly, Merck Partner to Evaluate DF9001 in Combination with Keytruda
    Dragonfly, Merck Partner to Evaluate DF9001 in Combination with Keytruda

    21 May 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-05-21/dragonfly-merck-partner-to-evaluate-df9001-in-combination-with-keytruda/?widget=listSection

    CONTRACT PHARMA
    21 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search